Real World Evidence Scientific Working Group

  • Session on Utility of Real-World Evidence in Medical Product Development and Life Cycle Management (ASA BIOP RISW 2018)
  • Emerging Opportunities for Utilizing Real-World Evidence to Impact Drug Development and Regulatory Decision-Making (Topic-contributed JSM 2019)
  • Recent Statistical Developments in Considering Real World Evidence for Regulatory Decision Making (2019 JSM)
  • Session on Challenges and Opportunities in the Use of Real-World Evidence in Regulatory Decision-Marking of Medical Products: An ASA BIOP RWE SWG Progress (ASA BIOP RISW 2019)
  • Invited session on Translating Real-World Data into Real-World Evidence for Regulatory Decisions and Medical Practice: Opportunities and Challenges (JSM 2020)
  • Session on Addressing Challenges and Opportunities in the Use of Real-World Evidence in Regulatory Decision-Marking of Medical Products: ASA BIOP RWE SWG Interim Progress report (ASA BIOP RISW 2020)
  • Session on Key Steps in Deriving Real-World Evidence from Analysis of Real-World Data –Topic-Contributed Papers (2021 JSM)
  • Session on Addressing Key Issues to Promote the Uptake of Using RWE/D for Regulatory Decisions – Topic-Contributed Papers (2022 JSM)